Abstract: Objective This paper focuses on the effect and safety evaluation of the therapy of exenatide for obese T2DM patients in the control of blood glucose, improvement of pancreatic beta cell function, alleviation of insulin resistance, evaluation of the incidence of adverse events and other aspects of efficacy and safety.Methods In this study, 60 cases of obese T2DM patients with undesirable blood glucose control results from oral administration of hypoglycemic agents were selected. Patients were randomly divided into exenatide group (n=30) and insulin aspart 30 group (n=30). Subcutaneous injection 5 μg exenatide twice a day was applied to the exenatide group, dosage was increased to 10 μg after one month; Subcutaneous injection of insulin aspart 30 twice a day was applied to the insulin aspart 30 group, initial dosages depending on the blood glucose level of patient. All injections were applied before meals with dosages adjusted every 1 or 2 days. Observing period lasted for 12 weeks. Information of patients in both groups before and after therapy were observed and recorded, such as general information, blood glucose, islet function, blood fat, insulin resistance index and also occurrence of adverse drug reaction and low glucose to determine its efficacy and safety.Results Blood glucose, body mass index, blood fat, insulin resistance index, the index of islet function in the exenatide group improved significantly better than insulin aspart 30 group(P<0.05),without hypoglycemia, and there were only slight gastrointestinal adverse reactions.Conclusion For obese patients with type 2 diabetes, the treatment effect is obviously better than insulin aspart 30, exenatide is one of the better alternative options than insulin aspart 30.

Key words: diabetes mellitus,type 2, glucagon-like peptide 1, metformin